Cargando…
Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varyi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/ https://www.ncbi.nlm.nih.gov/pubmed/24527096 http://dx.doi.org/10.3892/ol.2013.1756 |
_version_ | 1782303106660302848 |
---|---|
author | CHEN, XUEQIN PAN, YUELONG ZHANG, SHIRONG CHEN, DADONG YANG, SHAOYU LI, XIN MA, SHENGLIN |
author_facet | CHEN, XUEQIN PAN, YUELONG ZHANG, SHIRONG CHEN, DADONG YANG, SHAOYU LI, XIN MA, SHENGLIN |
author_sort | CHEN, XUEQIN |
collection | PubMed |
description | Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varying severity is overlooked in long-term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. The patient achieved partial clinical remission but developed drug-induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient’s liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib-induced hepatotoxicity. |
format | Online Article Text |
id | pubmed-3919904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-39199042014-02-13 Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review CHEN, XUEQIN PAN, YUELONG ZHANG, SHIRONG CHEN, DADONG YANG, SHAOYU LI, XIN MA, SHENGLIN Oncol Lett Articles Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varying severity is overlooked in long-term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. The patient achieved partial clinical remission but developed drug-induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient’s liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib-induced hepatotoxicity. D.A. Spandidos 2014-03 2013-12-11 /pmc/articles/PMC3919904/ /pubmed/24527096 http://dx.doi.org/10.3892/ol.2013.1756 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles CHEN, XUEQIN PAN, YUELONG ZHANG, SHIRONG CHEN, DADONG YANG, SHAOYU LI, XIN MA, SHENGLIN Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title | Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title_full | Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title_fullStr | Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title_full_unstemmed | Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title_short | Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review |
title_sort | rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: a case report and literature review |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/ https://www.ncbi.nlm.nih.gov/pubmed/24527096 http://dx.doi.org/10.3892/ol.2013.1756 |
work_keys_str_mv | AT chenxueqin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT panyuelong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT zhangshirong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT chendadong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT yangshaoyu rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT lixin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview AT mashenglin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview |